Advancing Antimicrobial Innovation
Through Science
Natureza® Research Addresses the Urgency of Antibiotic Resistance
THE PROBLEM:
Antibiotic-resistant infections are rising worldwide, yet the clinical pipeline remains weak (WHO 2019). Developing a new antibiotic takes 10–15 years and over $1 billion, but resistance can emerge within months, discouraging innovation—only two new classes have been created in 40 years. Lab studies show resistance evolving in days (Baym et al. 2016). We urgently need antibiotics with novel targets that resist resistance. Most critical pathogens are Gram-negative ESKAPE organisms, though some Gram-positives, like vancomycin-resistant Enterococcus faecium, are also high priority. New solutions must not only kill resistant bacteria but also prevent resistance from developing.
A SOLUTION:
Extensive lab studies have shown our active ingredient formulations effectively reduce infection rates in highly resistant pathogens like Candida auris and Pseudomonas aeruginosa without developing drug resistance. We are now advancing to preclinical trials aiming to build on this success. Introducing an approach that would eliminate bacterial resistance can dramatically reduce development costs. With drugs that remain effective for years, investors would have time to recover costs and earn profits. This shift would create a more favorable environment for antibiotic innovation, encouraging the development of urgently needed treatments.
ABOUT NATUREZA® RESEARCH
Natureza’s work builds on that of its parent company BioSafe Technologies, Inc, a Texas firm founded in 2000 which has invested in Natureza’s anti-parasitic, anti-bacterial research and provided management support. Natureza® Research, Inc. has developed anti-infectives and holds multiple U.S. and international patents for its agents which target WHO-priority Gram-negative and Gram-positive ESKAPE pathogens, including three actives against Priority 1 threats. Extensive pre-clinical studies have shown activity against 12 of 15 top resistant bacteria, without resistance developing. The agents are safe and GRAS-certified.
THE NATUREZA® TEAM
The Natureza Research team brings together decades of expertise in infectious disease, pharmaceutical development, and international collaboration. United by a shared mission, our team provides leadership in antimicrobial innovation—developing scientifically validated agents to address the global threat of antibiotic resistance which are testing nonresistant.
This work is protected by US and foreign patents and patents pending.
Advancing Antimicrobial Innovation Through Science
Natureza® Research Addresses the Urgency of Antibiotic Resistance
THE PROBLEM:
Antibiotic-resistant infections are rising worldwide, yet the clinical pipeline remains weak (WHO 2019). Developing a new antibiotic takes 10–15 years and over $1 billion, but resistance can emerge within months, discouraging innovation—only two new classes have been created in 40 years. Lab studies show resistance evolving in days (Baym et al. 2016). We urgently need antibiotics with novel targets that resist resistance. Most critical pathogens are Gram-negative ESKAPE organisms, though some Gram-positives, like vancomycin-resistant Enterococcus faecium, are also high priority. New solutions must not only kill resistant bacteria but also prevent resistance from developing.
A SOLUTION:
Extensive lab studies have shown our active ingredient formulations effectively reduce infection rates in highly resistant pathogens like Candida auris and Pseudomonas aeruginosa without developing drug resistance. We are now advancing to preclinical trials aiming to build on this success. Introducing an approach that would eliminate bacterial resistance can dramatically reduce development costs. With drugs that remain effective for years, investors would have time to recover costs and earn profits. This shift would create a more favorable environment for antibiotic innovation, encouraging the development of urgently needed treatments.
ABOUT NATUREZA® RESEARCH
Natureza’s work builds on that of its parent company BioSafe Technologies, Inc, a Texas firm founded in 2000 which has invested in Natureza’s anti-parasitic, anti-bacterial research and provided management support. Natureza® Research, Inc. has developed anti-infectives and holds multiple U.S. and international patents for its agents which target WHO-priority Gram-negative and Gram-positive ESKAPE pathogens, including three actives against Priority 1 threats. Extensive pre-clinical studies have shown activity against 12 of 15 top resistant bacteria, without resistance developing. The agents are safe and GRAS-certified.
THE NATUREZA® TEAM
The Natureza Research team brings together decades of expertise in infectious disease, pharmaceutical development, and international collaboration. United by a shared mission, our team provides leadership in antimicrobial innovation—developing scientifically validated agents to address the global threat of antibiotic resistance which are testing nonresistant.
This work is protected by US and foreign patents and patents pending.
